Alcoholic liver disease

Clinical Hepatology

Volumn 2, Issue , 2010, Pages 1111-1151

  Seitz, Helmut Karl ^a,b   Mueller, Sebastian ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Krankenhaus Salem   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889957591     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-04519-6_34     Document Type: Chapter

References (99)

1. Akriviadis E, Botla R, Briggs W, et al (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119:1637-48
2. Albano E (2006) Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 65:278-90
3. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209-18
4. Bell H, Tallaksen C, Sjaheim T, et al (1993) Serum carbohydratedeficient transferrin as a marker of alcohol consumption in patients with chronic liver diseases. Alcohol Clin Exp Res 17:246-52
5. Bellentani S, Saccoccio G, Costa G, et al (1997) Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 41:845-50
6. Bellentani S, Tiribelli C. (2001) The spectrum of liver disease in the general population: lesson from the Diagnosis study. J Hepatol 35:531-7
7. Bradford BU, Kono H, Isayama F, et al (2005) Cytochrome P450 CYP2E1, but not nicotinamide adenine dinucleotide phosphate oxidase, is required for ethanol-induced oxidative DNA damage in rodent liver. Hepatology 41:336-44
8. Burt AD, MacSwee R. (1999) Pathology of alcoholic liver disease. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J (eds) Oxford Textbook of clinical hepatology. Oxford University Press, Oxford, pp 1179-84
9. Caballeria J, Pares A, Bru C, et al (1998) Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 28:54-60
10. Cabre E, Rodriguez-Iglesias P, Caballeria J, et al (2000) Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 32:36-42
11. Chedid A, Mendenhall CL, Gartside P, et al (1991) Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 86:210-6
12. Cochrane J, Chen H, Conigrave KM, et al (2003) Alcohol use in China. Alcohol Alcohol 38:537-42
13. Colmenero J, Bataller R, Sancho-Bru P, et al (2007) Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology 132:687-97
14. Conn HO. (1982) Cirrhosis. In: Schiff ER, Schiff L (eds) Diseases of the liver. Lippincott, Philadelphia, pp 847-978
15. Corrao G, Arico S, Zambon A, et al (1997) Female sex and the risk of liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy. Scand J Gastroenterol 32:1174-80
16. Crabb DW. (1997) First pass metabolism of ethanol: gastric or hepatic, mountain or molehill? Hepatology 25:1292-4
17. Dan Z, Popov Y, Patsenker E, et al (2005) Hepatotoxicity of alcohol-induced polar retinol metabolites involves apoptosis via loss of mitochondrial membrane potential. FASEB J 19:845-7
18. Day CP. (2006) From fat to inflammation. Gastroenterology 130:207-10
19. Denk H, Stumptner C, Zatloukal K. (2000) Mallory bodies revisited. J Hepatol 32:689-702
20. Dunn W, Jamil LH, Brown LS, et al (2005) MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41:353-8
21. Dunn W, Angulo P, Sanderson S, et al (2006) Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 131:1057-63
22. Falck-Ytter Y, Younossi ZM, Marchesini G, et al (2001) Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 21:17-26
23. Felver ME, Mezey E, McGuire M, et al (1990) Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 14:255-9
24. Forrest EH, Evans CD, Stewart S, et al (2005) Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 54:1174-9
25. Frank A, Seitz HK, Bartsch H, et al (2004) Immunohistochemical detection of 1, N6-ethenodeoxyadenosine in nuclei of human liver affected by diseases predisposing to hepato-carcinogenesis. Carcinogenesis 25:1027-31
26. French SW, Barderyg-Gorce F (2005) Ubiquitin-protesasome pathway in the pathogenesis of liver disease. In: Dafour J, Clavier R (eds) Springer, Berlin, Heidelberg, New York, pp 377-90
27. Frezza M, Di Padova C, Pozzato G, et al (1990) High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322:95-9
28. Garbutt JC, West SL, Carey TS, et al (1999) Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281:1318-25
29. Gavaler J, Arria A. (1995) Increased susceptibility of women to alcoholic liver disease: artifactual or real?. In: Hall P (ed) Alcoholic liver disease. Edward Arnold, London/Boston/Melbourne/Auckland, pp. 123-33
30. Gouillon Z, Lucas D, Li J, et al (2000) Inhibition of ethanolinduced liver disease in the intragastric feeding rat model by chlormethiazole. Proc Soc Exp Biol Med 224:302-8
31. Hall P (1995) Pathological spectrum of alcoholic liver disease. In: Hall P (ed) Alcoholic liver disease. Edward Arnold, London/Boston/Melbourne/Auckland, pp. 41-70
32. Halstedt C (1999) Role of nutrition in the treatment of alcoholic liver disease. In: Arroyo V, Bosch J, Bruguera M, Rodes J, Sanchez-Tapia J (eds) Masson, Barcelona, pp. 221-232
33. Higuchi S, Matsushita S, Imazeki H, et al (1994) Aldehyde dehydrogenase genotypes in Japanese alcoholics. Lancet 343:741-2
34. Hurley T, Edenberg H, Li T (2002) Pharmacogenomics of Alcoholism. In: Licinio J, Wong M (eds) Pharmacogenomics - The search for individualized therapies. Wiley VCH, Weinheim
35. Jahrbuch-Sucht. (2007). Neuland Verlagsgesellschaft mbH
36. Koch H, Meerkerk GJ, Zaat JO, et al (2004) Accuracy of carbohydrate-deficient transferrin in the detection of excessive alcohol consumption: a systematic review. Alcohol Alcohol 39:75-85
37. Lelbach WK. (1975) Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci 252:85-105
38. Leo MA, Kim C, Lowe N, et al (1992) Interaction of ethanol with beta-carotene: delayed blood clearance and enhanced hepatotoxicity. Hepatology 15:883-91
39. Lieber CS. (1994) Alcohol and the liver: 1994 update. Gastroenterology 106:1085-105
40. Lieber CS. (1999) Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol Clin Exp Res 23:991-1007
41. Lieber CS. (2001) Alcoholic liver disease: natural course, mechanisms and therapeutic strategies. In: Boyer J, Blum H, Maier K, Sauerbruch T, Stalder G (eds) Liver cirrhosis and its development. Kluwer, Dordrecht
42. Lieber CS, Weiss DG, Groszmann R, et al (2003) II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 27:1765-72
43. Lochs H, Plauth M. (1999) Liver cirrhosis: rationale and modalities for nutritional support - the European Society of Parenteral and Enteral Nutrition consensus and beyond. Curr Opin Clin Nutr Metab Care 2:345-9
44. Louvet A, Naveau S, Abdelnour M, et al (2007) The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 45:1348-54
45. Lumeng L, Crabb DW. (2001) Alcoholic liver disease. Curr Opin Gastroenterol 17:211-20
46. Maddrey WC, Boitnott JK, Bedine MS, et al (1978) Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75:193-9
47. Maher J. (2002) Alcoholic liver disease. In: Feldman M, Friedman LS, Sleisenger MH, eds. Gastrointestinal and Liver Disease. Volume II. WB Saunders, Philadelphia, pp 1375-91
48. Mathurin P, Mendenhall CL, Carithers RL, Jr., et al (2002) Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36:480-7
49. Mato JM, Camara J, Fernandez De Paz J, et al (1999) S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 30:1081-9
50. McCullough AJ, O'Connor JF. (1998) Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 93:2022-36
51. Mendenhall C, Bongiovanni G, Goldberg S, et al (1985) VA Cooperative Study on Alcoholic Hepatitis. III: Changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. JPEN J Parenter Enteral Nutr 9:590-6
52. Mendenhall CL, Anderson S, Garcia-Pont P, et al (1984) Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 311:1464-70
53. Mendenhall CL, Moritz TE, Roselle GA, et al (1993) A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 17:564-76
54. Mezey E. (1998) Dietary fat and alcoholic liver disease. Hepatology 28:901-5
55. Moreau K, Mueller P, Driesch D, et al (1992) Trauma in cirrhosis: an indicator of the pattern of alcohol abuse in different societies. Alcoholism Clin Exp Res 16:141-3
56. Morgan M. (1999) Alcoholic liver disease: natural history, diagnosis, clinical feature, evaluation, management, prognosis, and prevention. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J (eds) Oxford textbook of clinical hepatology. Oxford University Press, Oxford, pp 1186-238
57. Nair S, Mason A, Eason J, et al (2002) Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36:150-5
58. Naveau S, Chollet-Martin S, Dharancy S, et al (2004) A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39:1390-7
59. Niemela O. (2007) Acetaldehyde adducts in circulation. Novartis Found Symp 285:183-92; discussion 193-7
60. Nissenbaum M, Chedid A, Mendenhall C, et al (1990) Prognostic significance of cholestatic alcoholic hepatitis. VA Cooperative Study Group #119. Dig Dis Sci 35:891-6
61. Ohnishi K, Iida S, Iwama S, et al (1982) The effect of chronic habitual alcohol intake on the development of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface antigen carriage. Cancer 49:672-7
62. Oneta CM, Simanowski UA, Martinez M, et al (1998) First pass metabolism of ethanol is strikingly influenced by the speed of gastric emptying. Gut 43:612-9
63. Oneta CM, Lieber CS, Li J, et al (2002) Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J Hepatol 36:47-52
64. Orrego H, Israel Y, Blake JE, et al (1983) Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 3:896-905
65. Pequignot G. (1974) Les problemes nutritionelles de la societe industrielle. La vie medicale en Canada francais 3:216-55
66. Purohit V, Brenner DA. (2006) Mechanisms of alcoholinduced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 43:872-8
67. Ramond MJ, Poynard T, Rueff B, et al (1992) A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 326:507-12
68. Raynard B, Balian A, Fallik D, et al (2002) Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 35:635-8
69. Rehm J, Room R, Monteiro R, et al (2004) Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. In: Ezatti M, Murray C, Lopez AD, Rodgers A, Murray C (eds) Comparative quantification of health risks. World Health Organisation, Geneva
70. Salaspuro M. (1999) Epidemiological aspects of alcohol and alcoholic liver disease, ethanol metabolism, and pathogenesis of alcoholic liver injury. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodes J (eds) Oxford textbook of clinical hepatology. Oxford University Press, Oxford, pp 791-810
71. Salaspuro MP (2003) Acetaldehyde, microbes, and cancer of the digestive tract. Crit Rev Clin Lab Sci 40:183-208
72. Salmela KS, Roine RP, Hook-Nikanne J, et al (1994) Acetaldehyde and ethanol production by Helicobacter pylori. Scand J Gastroenterol 29:309-12
73. Saunders JB, Walters JR, Davies AP, et al (1981) A 20-year prospective study of cirrhosis. Br Med J (Clin Res Ed) 282:263-6
74. Seitz HK, Meydani M, Ferschke I, et al (1989) Effect of aging on in vivo and in vitro ethanol metabolism and its toxicity in F344 rats. Gastroenterology 97:446-56
75. Seitz HK, Egerer G, Simanowski U. (1990) High blood alcohol levels in women. N Engl J Med 323:58-59
76. Seitz HK, Oneta CM. (1998) Gastrointestinal alcohol dehydrogenase. Nutr Rev 56:52-60
77. Seitz HK, Poschl G, Simanowski UA. (1998) Alcohol and cancer. Recent Dev Alcohol 14:67-95
78. Seitz HK, Suter P. (2002) Ethanol toxicity and nutritional status. In: Kotsonis F, Mackey M (eds) Nutritional toxicology, 2nd ed. Taylor & Francis, London/New York, pp 122-54
79. Seitz HK. (2006) Additive effects of moderate drinking and obesity on serum gamma-glutamyl transferase. Am J Clin Nutr 83:1252-3
80. Seitz HK, Stickel F (2006) Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 387:349-60
81. Seitz HK, Becker P (2007) Alcohol-induced hepatitis: Pathophysiology and treatment. In: Diehl A, Hayashy N, Manns M, Sauerbruch T (eds) Chronic hepatitis: metabolic, cholestatic, viral and autoimmun.: Kluwer, Dordrecht/Boston/London, pp. 16-31
82. Seitz HK, Stickel F (2007) Molecular mechanisms of alcoholmediated carcinogenesis. Nat Rev Cancer 7:599-612
83. Seth D, Gorrell MD, Cordoba S, et al (2006) Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol 45:306-20
84. Simonis B, Reimann FM, Waldherr R, et al (2007) Sonographic course of alcoholic fatty liver by interobserver and digital evaluation of liver echogenicity. Zeitschr. Gastroenterol 45:689-96
85. Slattery JT, Nelson SD, Thummel KE. (1996) The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 60:241-6
86. Spahr L, Rubbia-Brandt L, Frossard JL, et al (2002) Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 37:448-55
87. Stickel F, Urbaschek R, Schuppan D, et al (2001) Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci 46:2025-32
88. Stickel F, Schuppan D, Hahn EG, et al (2002) Cocarcinogenic effects of alcohol in hepatocarcinogenesis. Gut 51:132-9
89. Stickel F, Hoehn B, Schuppan D, et al (2003) Review article: Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 18:357-73
90. Stickel F, Osterreicher CH. (2006) The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 41:209-24
91. Teli MR, Day CP, Burt AD, et al (1995) Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 346:987-90
92. Teschke R. (2003) Alkoholische Lebererkrankungen. In: Dancygier H, ed. Klinische Hepatologie. Springer Verlag, Berlin, pp 609-58
93. Thun MJ, Peto R, Lopez AD, et al (1997) Alcohol consumption and mortality among middle-aged and elderly U. S. adults. N Engl J Med 337:1705-14
94. Thurman RG (1998) II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 275:G605-11
95. Tilg H, Diehl AM (2000) Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343:1467-76
96. Tilg H, Jalan R, Kaser A, et al (2003) Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38:419-25
97. Tilg H, Day CP. (2007) Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 4:24-34
98. Urbaschek R, McCuskey RS, Rudi V, et al (2001) Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res 25:261-8
99. Westin J, Lagging LM, Spak F, et al (2002) Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 9:235-41